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Abstract
Background: Impaired thrombin generation (TG) in patients with acquired coagulop-
athy, is due to low coagulation factors and thrombocytopenia. The latter is typically 
treated with platelet transfusions and the former with plasma and occasionally with 
prothrombin complex concentrates (PCCs). We hypothesized that manipulating the 
concentrations of coagulation factors might result in restoration of platelet-depend-
ent TG over and above that of simple replacement therapy.
Objective: To investigate the influence of PCCs on impaired TG secondary to 
thrombocytopenia.
Methods: TG was evaluated by thrombin generation assay using a thrombocytopenia 
model in which normal plasma samples with varying platelet counts (20-300 × 109/L) 
were spiked with PCCs (25%-150% increase in plasma PCC levels).
Results: PCCs and platelets significantly increased TG in a dose-dependent manner 
in vitro. Two-way repeated measures of analysis of variance showed variance in peak 
height, area under the curve, time to peak, and velocity. This variance explained, 
respectively, by levels of PCC was 47, 59, 25 and 53%; by platelet count was 45, 28, 
44, and 14%; by the combination was 80, 67, 70, and 62% variance; and a combi-
nation with additional interaction was 91, 84, 76, and 68%. TG at a platelet count 
40 × 109/L with an approximate 25% increase in PCC concentration was similar to 
TG at 150 × 109/L. Similarly, patient samples spiked ex vivo with PCCs also showed 
highly significant improvements in TG.
Conclusions: Impaired TG of thrombocytopenia is improved by PCCs, supporting the 
need for additional studies in complex coagulopathies characterized by mild to mod-
erate thrombocytopenia and abnormal coagulation.
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Essentials
• Bleeding tendency of acquired coagulopathy (AC) is due to low coagulation factors and platelets.
• Increasing platelet count and clotting factors independently increases thrombin generation (TG).
• In an in vitro thrombocytopenia model, prothrombin complex concentrates (PCCs) normalized TG at standard doses.
• The effect of PCCs in AC is beyond simple replacement therapy.
1  | INTRODUC TION
Thrombin is the final common enzyme of the coagulation cascade 
and is responsible for fibrin polymerization and clot formation. 
Impaired thrombin generation is typically seen in acquired he-
mostatic abnormalities commonly caused by liver disease, major 
trauma, critical illness, and dilutional coagulopathy, and can ag-
gravate ongoing bleeding or increase the risk of bleeding. These 
abnormalities present singly or as variable combinations of coagu-
lopathy, thrombocytopenia, hypofibrinogenemia, and hyperfibrinol-
ysis.1 Restoration of thrombin generation (TG) and clot formation 
are vital for arresting or preventing bleeding. Treatments for these 
abnormalities include plasma or prothrombin complex concentrates 
(PCCs), platelet transfusions, fibrinogen or cryoprecipitate infu-
sions, and tranexamic acid.
Treatment is instituted either prophylactically to prevent 
periprocedural bleeding or therapeutically for the management of 
active bleeding. The pathogenesis of bleeding in these situations is 
multifactorial, and patients often receive more than 1 form of ther-
apy for correction of abnormalities. Thresholds have been defined 
by various guidelines for transfusion of plasma, PCC, platelets, cryo-
precipitate, fibrinogen, and tranexamic acid.2‒8 However, there are 
very few data available on the interaction between the various defi-
cient components and TG and clot formation.
Adequate TG is dependent on the interaction of the procoag-
ulant and anticoagulant pathways along with platelets and tissue 
factor–bearing cells.9 Increasing platelet count and prothrombin 
concentration independently demonstrate significant impacts on 
the rate and magnitude of TG.10,11 Variation in levels of prothrombin 
and antithrombin within the normal range cause significant changes 
in the rate, peak, and total amount of thrombin generated in in vitro 
models.12,13
Similarly, decreasing platelet counts have been associated 
with lower maximal rate of TG, lower peak, and time to peak 
(TTP) thrombin in models of thrombocytopenia, particularly at 
counts < 50 × 109/L.14 The rate of TG and peak TG continue to in-
crease until a platelet count of 300 to 500 × 109/L when values pla-
teau, although the area under the curve (AUC), lag time, and TTP 
plateau earlier at around 100 × 109/L.15 A 3- to 5-fold variation in 
the ability of platelets to support TG has also been demonstrated.16
The use of prohemostatic agents for management of thrombocy-
topenia is not a new concept. In a small clinical study, administration 
of recombinant factor VIIa (rFVIIa) stopped overt bleeding in 6 of 8 
patients with severe thrombocytopenia.17
In the context of impaired platelet-dependent TG, demonstra-
ble with thrombocytopenia, we hypothesized that the addition of 
PCCs will result in restoration of TG. PCCs were chosen rather than 
purified coagulation factors as PCCs are regularly used for the man-
agement of acquired coagulopathy. Furthermore, standard doses of 
PCCs provide a greater concentration of clotting factors in compar-
ison with standard doses of plasma, and the effect is similar to that 
seen with higher volumes of plasma.18,19 To investigate our hypothe-
sis, we evaluated the influence of PCCs on TG in an in vitro model of 
thrombocytopenia over a range of platelet counts (20-300 × 109/L) 
by thrombin generation assay (TGA). This was further evaluated by 
TGA analysis of blood samples from patients with thrombocytopenia 
and varying degrees of coagulopathy following ex vivo spiking with 
PCCs.
2  | METHODS
2.1 | Study design
This in vitro/ex vivo spiking laboratory study was performed 
on venous blood samples from healthy volunteers and patients 
with thrombocytopenia. The study had ethical approval from the 
Katharine Dormandy Coagulation Research Plasma Bank (REC 
No:14/YH/1272) and relevant institutional approvals. Written in-
formed consent was obtained from all patients and volunteers.
2.2 | Healthy volunteers and patients
Five healthy volunteers and 21 patients with thrombocytopenia 
(platelet count < 80 × 109/L) were included. To understand if the 
effect of PCC was related to underlying coagulopathy, 2 groups of 
patients with thrombocytopenia were identified. The first was pa-
tients with liver disease with acquired coagulopathy (International 
Normalized Ratio [INR] >1.5), and the second was thrombocytopenia 
K E Y W O R D S
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secondary to myelosuppressive chemotherapy with no active 
infection.
2.3 | Venous blood collection and sample 
preparation
Thirty milliliters of venous blood for TGA analysis was collected 
from antecubital veins with a 21-gauge butterfly needle into cit-
rated S-Monovette tubes (citrate 3.2%; Sarstedt AG, Numbrecht, 
Germany) with added corn trypsin inhibitor (CTI; final concentration 
18 μg/mL; Cambridge Biosciences, Cambridge, UK).
Blood from 5 healthy volunteers was rested for 30 minutes at 
room temperature, and platelet-rich plasma (PRP) was prepared by 
centrifugation for 15 minutes at 190 g. Platelet-poor plasma (PPP) 
was prepared from the remaining sample by double centrifugation 
at 2000 g for 15 minutes. PRP with a range of platelet counts was 
prepared by resuspending the PRP of a known platelet count with 
autologous double-spun PPP, with counts confirmed using an XS-
1000i full blood count analyzer (Sysmex Corporation, Kobe, Japan).
2.4 | PCC concentration for spiking experiments
The PCC used was Beriplex (CSL Behring, Marburg, Germany) con-
taining procoagulant proteins factor II (prothrombin), factor VII, 
factor IX, and factor X; anticoagulant proteins C and S; and small 
quantities of antithrombin and heparin.20 Since even small quantities 
of heparin interfere with the coagulation assays,21 it was neutral-
ized with Hepzyme (removes ≤ 2 USP U/mL unfractionated heparin 
from 1 mL plasma; Dade Behring/Siemens Healthcare Diagnostics 
Products GmbH, Marburg, Germany), and removal was confirmed 
by an anti-Xa heparin assay.22 Clotting factors were measured and 
found not to be affected by Hepzyme treatment (results not shown). 
Beriplex was reconstituted according to the manufacturer’s instruc-
tions and, following treatment with Hepzyme, frozen in aliquots at 
−45°C.
In line with PCC labeling, the assigned factor IX potency was 
used as the reference for quantifying the amount of PCC used for 
spiking; hereafter, the strength of PCC concentration refers to the 
labeled potency. The concentration of factor IX in the reconstituted 
lot of PCC after treatment with heparinase was 23 IU/mL, while the 
concentrations of prothrombin, factor X, factor VII, protein C, and 
protein S were 22, 30, 19, 30, and 25 IU/mL, respectively, as mea-
sured by 1-stage clotting assays (prothrombin, factor VII, factor IX, 
and factor X), chromogenic assay (protein C activity), and latex anti-
gen (free protein S).
Four concentrations of PCCs were used in the spiking experi-
ments, and the lowest strength was 3.3 μL of reconstituted hepari-
nase-treated PCC at 1:3 dilution in Owren’s Buffered Saline (OBS), 
followed by 3.3 μL at a 1:1 dilution in OBS, and 3.3 μL and 4.9 μL 
undiluted PCC, equating to an increase of PCC concentration in the 
plasma of 0.26 IU/mL, 0.52 IU/mL, 1.03 IU/mL, and 1.53 IU/mL.
2.5 | TG and in vitro spiking with 
PCCs of thrombocytopenic plasma obtained from 
healthy volunteers
The TG assay was undertaken using a Spectramax i3x microtiter 
plate reader (Molecular Devices UK Ltd, Berkshire, UK), where TG 
was measured using the same substrate as the Thrombinoscope 
method (in the absence of calibrator) in a microtiter plate (Immulon 
2B, Thermo Fisher Scientific, Waltham, MA, USA), and recorded 
in relative fluorescence units (RFU).12,23,24 Initial TG experiments 
were conducted on a calibrated automated thrombogram (CAT) 
machine (Thrombinoscope BV, Maastricht, The Netherlands) in-
cluding incorporation of an internal calibrator.25 Increases in PCC 
at the higher end resulted in depletion of the thrombin-specific 
fluorescent substrate and an inability to bring assays to closure. In 
patient samples, the highest dose was dropped and samples ana-
lyzed on a CAT.
TG was undertaken in PRP with a range of platelet counts (20, 
40, 60, 90, 150, 225, and 300 × 109/L).
For the TG assay, 20 μL of 0.5 PM tissue factor (TF) trigger 
(Dade Innovin, Siemens Healthcare Diagnostic Products GmbH, 
Marburg, Germany) was added to a 96-well round-bottomed plate 
in duplicate for each test. Eighty microliters of PRP was added, and 
the plate was incubated for 5 minutes at 37°C inside the microti-
ter plate reader. TG was initiated with the addition of 20 μL FluCa 
(0.1 M CaCl2/Fluorogenic substrate 2.5 mM Z-Gly-Gly-Arg-AMC.
HCl; Thrombinoscope BV, Maastricht, The Netherlands) and mea-
sured kinetically at 390/460 nM over 60 minutes at 37°C. All sam-
ples were measured in duplicate using PRP at each platelet count, 
while PPP, with and without added PCCs, was run in parallel. The 
control included PPP in which TG was triggered with the same 
0.5 PM TF trigger without added phospholipid. This was done to 
identify any significant background activity related to PCCs alone 
and as a comparator to demonstrate the impact of increasing platelet 
count. Measured and derived TG parameters analyzed included peak 
height (PH) in RFU, AUC in RFU, TTP in minutes, and the maximum 
rate of TG in RFU/sec (Vmax). PH, AUC, and TTP were calculated as 
previously described,12,23 and Vmax was provided by Spectramax i3x 
software (Soft Max Pro 6.4; Molecular Devices Ltd, San Jose, CA, 
USA). A single batch of freeze-thawed platelets was run as control 
for all experiments, and the interrun variability was 11% for the PH 
and 16% for AUC.
2.6 | Ex vivo spiking of patient samples—thrombin 
generation assay
Ten milliliters of blood from patients was collected into 3.2% so-
dium citrate tubes to which CTI had been added, as described 
above, and left at room temperature for 30 minutes. TG assays 
were performed on patients’ PRP on the Spectramax without ad-
justment of platelet counts as for the normal donor samples, with 
and without PCC.
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2.7 | Statistical analysis
For the in vitro thrombocytopenia model, TG at a platelet count of 
150 × 109/L with no added PCC was considered normal and assigned 
a value of 0. The percent differences (percent increase or decrease) 
between normal and the range of PRP platelet counts spiked with in-
creasing concentrations of PCCs for TG parameters PH, AUC, TTP, and 
Vmax (RFU/sec) were calculated and data presented graphically.
Two-way repeated measures analysis of variance (ANOVA) was 
carried out on the healthy volunteer samples to assess the effects 
of PCC concentration and the PRP platelet count simultaneously, 
together and with the interaction between them (ie, additive and 
synergistic effects), for each of the 4 thrombin clotting parameters. 
Variances both between and within samples were summed, and the 
percentage of variance explained by PCC and platelets separately 
was calculated, as well as the percentage explained by these two 
variables in combination.
Similar analyses were carried out on repeated measures of sam-
ples from patients with thrombocytopenia to investigate the effect 
of adding PCC. We assessed the effect of any dose versus no dose 
at all and the effects of different doses. Repeated measures were 
available for each sample for every level of PCC concentration.
All analyses were carried out in Stata, version 15.1 (StataCorp 
LLC, College Station, TX, USA).
3  | RESULTS
3.1 | PCCs improve and increase thrombin 
generation in thrombocytopenic normal plasma in a 
dose-dependent manner
TG in PRP was measured over a range of platelet counts (20, 40, 60, 
90, 150, 225, and 300 × 109/L) with and without the addition of 4 
different strengths of PCCs (spiked plasma concentrations of 0.26, 
0.52, 1.03, and 1.53 IU/mL). In the absence of PCCs, lower platelet 
counts were associated with lower PH, AUC, Vmax, and increased 
TTP, and the AUC appears to plateau when platelet counts reach 
normal levels. Two-way repeated measures ANOVA showed that 
increasing concentrations of PCCs significantly increased PH and 
AUC, shortened TTP, and increased Vmax/sec, P < 0.001 for all ex-
cept TTP (P = 0.01). Similarly, increasing platelet count significantly 
increased PH, AUC, shortened TTP, and increased Vmax, P < 0.001 
for all except Vmax (P = 0.02). Furthermore, the variance in PH, AUC, 
TTP, and Vmax explained by levels of PCC was 47, 59, 25, and 53% 
respectively, and by platelet count was 45, 28, 44, and 14%, respec-
tively, suggesting important contributions from both components. A 
combination of PCC and platelet count accounted for 80, 67, 70, and 
62% variance and a combination with additional interaction between 
PCC and platelet count accounted for 91, 84, 76, and 68% variance, 
respectively.
Changes in TG parameters in relation to platelet count and PCC 
concentration are presented in Figure 1, where zero represents the 
“normal baseline TG” at a PRP platelet count of 150 × 109/L without 
the addition of PCCs.
Following ex vivo spiking with PCCs, similar increases of proco-
agulant factors prothrombin, factor VII, factor IX, and factor X, and 
anticoagulant proteins C and S were seen, which were proportionate 
to the dose (data not shown). This is in contrast to the increases seen 
clinically, where variable increases of different factors are seen due 
to the differences in the volume of distribution.
Increasing PCC concentration by 0.52 IU/mL with a platelet count 
of 20 × 109/L, and by 0.26 IU/mL with a platelet count of 40 × 109/L 
resulted in TG similar to that observed in normal plasma at a platelet 
count of 150 × 109/L (Figure 2).
3.2 | Thrombocytopenic patient blood samples 
following ex vivo spiking with PCCs show increases in 
thrombin generation
The findings in the in vitro thrombocytopenic model generated 
from healthy volunteers were replicated in PRP samples from pa-
tients with thrombocytopenia and varying severity of coagulopathy. 
Whole blood samples from patients with normal INR and low platelet 
counts secondary to chemotherapy between 7 and 73 × 109/L were 
analyzed without PCC and with PCC (spiked plasma concentrations 
0.26, 0.52, and 1.03 IU/mL) similar to the healthy volunteer sam-
ples. Whole blood samples from patients with liver disease included 
a range of INRs between 1.6 and 2.2, platelet counts (26-72 × 109/L), 
and fibrinogen levels (<0.4-6.0 g/L). This group was included to as-
sess the impact, if any, of concurrent coagulopathy.
The baseline values and results following spiked PCCs of patient 
samples in TG are presented in Table 1 and Figure 3. In samples from 
patients with liver disease with thrombocytopenia, spiking with PCC 
at any concentration was associated with statistically significant in-
creases in PH, AUC, and Vmax (Figure 3A-C) with no effect on TTP 
(P = 0.19; data not shown). Dose-dependent increases were also 
significant for PH, AUC, and Vmax with no effect on TTP; data not 
shown). The lack of obvious impact on TTP may be related to the 
already shortened TTP.
Similarly, in samples from patients with thrombocytopenia sec-
ondary to chemotherapy spiking with PCC resulted in statistically 
significant increases in PH, AUC, and Vmax (Figure 3 D-F) with no ef-
fect on TTP (P = 0.21; data not shown). Dose-dependent increases 
were also significant for PH, AUC, and Vmax with some effect on 
TTP (P = 0.011; data not shown). These findings were consistent 
with those observed in the healthy volunteer thrombocytopenia 
model.
4  | DISCUSSION
Thrombin generation in plasma is influenced by both platelets and 
coagulation factors. High levels of coagulation factors, in particu-
lar prothrombin, and high platelet counts are associated with an 
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increased rate of TG (Vmax), shorter TTP, higher peak thrombin, 
and increased quantity of thrombin (AUC).10,11,13,26 We have dem-
onstrated in an in vitro model of thrombocytopenia that increas-
ing the concentration of procoagulants, through addition of PCCs 
available for clinical use, improved the decreased TG secondary to 
thrombocytopenia to within and above the normal range. The TG 
pattern seen following the addition of PCCs appears to be similar 
to that with increasing prothrombin concentration26 and increasing 
platelet count.15 The improvement in TG was confirmed in throm-
bocytopenic patient blood samples following spiking with PCCs. 
This effect might explain the slightly superior clinical effectiveness 
of PCCs demonstrated in acquired coagulopathy when compared to 
plasma.27
In our in vitro spiking experiments, the TG curve showed a 
dose-dependent improvement in all parameters in relation to in-
creasing platelet count and increasing PCC concentration. The im-
provement with increases in platelet counts appears more modest 
compared to the change with higher concentrations of PCC, where 
no plateau was demonstrated despite the concurrent increase in 
proteins C and S. Further, higher PCC doses were associated with 
TG beyond the normal range. Our results show that TG is extremely 
sensitive to an increase in procoagulants, even in the presence of 
normal levels of clotting factors. In our study, the variance in PH, 
AUC, TTP, and Vmax explained by PCC concentration or platelet 
count suggested important contributions from both components. 
The variance explained by PCC was 47, 59, 25, and 53% for PH, 
F I G U R E  1   Percent change in PRP thrombin generation parameters (A) PH, (B) AUC, (C) TTP, and (D) Vmax without PCC and with PCC 
over a range of platelet counts compared to “normal baseline” defined as TG at a PRP platelet count of 150 × 109/L without PCC. Normal 
baseline was defined as TG at a PRP platelet count of 150 × 109/L without PCC triggered with 0.5 PM tissue factor and is represented by 
the horizontal line at zero. Percent change in TG from baseline “0” before and after the addition of PCC was calculated over a range of 
PRP platelet counts (20-300 × 109/L) (n = 5 normal donors) and PPP without phospholipid, all triggered with 0.5 PM tissue factor. Four 
concentrations of PCC were added corresponding to an increase in plasma PCC concentration of 0.26 (red), 0.52 (blue), 1.03 (green), and 
1.53 IU/mL (brown). No PCC is represented by black color. At around a platelet count of 90 × 109/L, the effect of increasing platelet count 
appears to plateau. PCCs at 0.26 IU/mL resulted in normalization of the TG assay, and at 0.52 IU/mL resulted in about a 1-fold increase in 
TG when compared to TG achieved at 150 × 109/L without PCC. At the same platelet count, the 2 higher concentrations resulted in TG 
parameters that were suggestive of hypercoagulability. AUC, area under the curve; PCC, prothrombin complex concentrate; PH, peak height; 
PPP, platelet-poor plasma; PRP, platelet-rich plasma; TG, thrombin generation; TTP, time to peak; Vmax, maximum velocity
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AUC, TTP, and Vmax, respectively, while the variance accounted for 
by platelet count was 45, 28, 44, and 14%, respectively, with PCCs 
having the least impact on TTP and platelets on Vmax. When these 
were combined, this increased to 80, 67, 70, and 62% of variance, 
respectively, and was even higher when a combination with addi-
tional interaction between PCC and platelet count was considered 
TA B L E  1   Thrombin generation measurement before and after the addition of PCC at three concentrations
Spiked 
plasma 
concentration 
of PCC
Normal (n = 5), PRP 150 Normal (n = 5), PRP 90 Normal (n = 5), PRP 40
Thrombocytopenia with 
prolonged INRa, n = 9
Thrombocytopenia with 
normal coagulationb, 
n = 10
Peak AUC Vmax Peak AUC Vmax Peak AUC Vmax Peak AUC Vmax Peak AUC Vmax
Baseline 0.41 
(0.07)
560 
(100)
0.16 
(0.04)
0.31 
(0.06)
480 
(99)
0.13 
(0.03)
0.22 
(0.06)
420 
(94)
0.12 
(0.03)
0.26 
(0.13)
310 
(150)
0.092 
(0.05)
0.27 
(0.18)
400 
(170)
0.12 
(0.05)
0.26 IU/mL 0.73 
(0.10)
970 
(92)
0.22 
(0.03)
0.55 
(0.08)
780 
(91)
0.18 
(0.03)
0.41 
(0.08)
660 
(100)
0.17 
(0.03)
0.38 
(0.23)
550 
(330)
0.116 
(0.10)
0.37 
(0.19)
560 
(290)
0.18 
(0.09)
0.52 IU/mL 0.91 
(0.10)
1200 
(150)
0.25 
(0.05)
0.78 
(0.12)
1100 
(240)
0.26 
(0.04)
0.52 
(0.09)
820 
(110)
0.20 
(0.03)
0.57 
(0.30)
706 
(420)
0.23 
(0.11)
0.43 
(0.25)
660 
(320)
0.22 
(0.10)
1.03 IU/mL 1.1 
(0.13)
1300 
(150)
0.26 
(0.03)
0.96 
(0.13)
1320 
(240)
0.31 
(0.04)
0.68 
(0.09)
1100 
(97)
0.28 
(0.03)
0.69 
(0.85)
890 
(490)
0.30 
(0.16)
0.53 
(0.36)
890 
(540)
0.27 
(0.13)
Note: Values for normal donor PRP at 3 platelet counts and patients with thrombocytopenia and abnormal coagulation (liver disease) and 
thrombocytopenia and normal coagulation (chemotherapy) are included. Values in table are given as × 106, presented as mean (1 standard deviation).
The unit of measure is relative fluorescence units, where Vmax is RFU/sec.
Abbreviations: AUC, area under the curve; INR, International Normalized Ratio; PCC, prothrombin complex concentrate; PRP, platelet-rich plasma; 
Vmax, maximum velocity.
aLiver disease. 
bSecondary to chemotherapy. 
F I G U R E  2   TG curves in (A) PPP, (B) PRP from one representative donor across a range of platelets counts (20-300 × 109/L), (C) PRP with 
platelet count of 20 × 109/L without PCC and added PCC compared to platelet count of 150 × 109/L without PCC, and (D) PRP with platelet 
count of 40 × 109/L without PCC and added PCC compared to platelet count of 150 × 109/L without PCC. TG is measured as change in RFU 
over time. PRP TG was measured over a range of platelet counts in parallel to PPP without phospholipid after triggering with 0.5 PM tissue 
factor. (A) TG in PPP at baseline without PCC (black), and with the addition PCC at 3 concentrations corresponding to 0.26 (red), 0.52 (blue), 
and 1.03 (green) IU/mL increase in PCC concentration is presented. (B) TG curves for PPP without phospholipid (black) and the range of 
increasing platelet counts (20, 40, 60, 90, 150, 225, and 300 × 109/L) where corresponding colors are indicated. PRP 150 × 109/L is colored 
blue. (C) TG at PRP count 20 × 109/L without PCC (red) and after the addition of PCC at 0.52 IU/mL (black hashed) is compared to PRP 
150 × 109/L without PCC (blue). (D) TG at PRP count of 40 × 109/L without PCC (green) and after the addition of PCC at 0.26 IU/mL (black 
hashed) is compared to PRP 150 × 109/L with no PCC added (blue). PCC, prothrombin complex concentrate; PPP, platelet-poor plasma; PRP, 
platelet-rich plasma; RFU, relative fluorescence unit; TG, thrombin generation
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(91, 84, 76, and 68%, respectively). An increase in total and peak 
thrombin in response to increasing prothrombin concentration has 
previously been demonstrated by other groups.28 We believe that 
the significant effect of the PCCs was related to the prothrombin 
levels. In a cell-based model of coagulation, near maximal TG was 
seen with factor X levels of around 10%, and the rate, peak, and AUC 
of TG continued to increase in a near-linear fashion as the concen-
tration of prothrombin was increased, with no evidence of saturation 
of the prothrombinase complex.26 However, in a porcine model of 
dilutional coagulopathy, PCC administration was associated with a 
sustained increase in TG, unlike recombinant human prothrombin, 
which produced a transient increase.29
Importantly, an approximate 25% increase in PCC concentration 
at a platelet count of 40 × 109/L, and 50% increase at a platelet count 
of 20 × 109/L, resulted in TG that would normally be associated with 
a platelet count of 150 × 109/L and normal levels of coagulation 
factors. Thus, PCCs administered at doses in use in current clinical 
practice produce an improvement of TG across all platelet counts, 
but the beneficial effect is marked at lower levels of platelets. Higher 
doses of PCCs were associated with TG beyond the normal range 
with no ceiling, suggesting potential for hypercoagulability if used 
inappropriately.
Furthermore, administration of PCC resulted in an improvement 
in all TG parameters, unlike rFVIIa, which demonstrated short-
ened lag time and increased rate of TG with no influence on PH or 
AUC.14,30
Our study has some important limitations. It is an in vitro laboratory 
study and may be disproportionately sensitive to spiking with PCCs. 
The use of PCCs to compensate for severe thrombocytopenia does 
not take into consideration the role of platelets in primary hemostasis. 
While TG tests are informative with regard to mechanisms, they do 
not necessarily reflect the bleeding situation. We have not undertaken 
F I G U R E  3   TG in thrombocytopenia samples from patients with and without the addition of PCC. TG was performed on PRP from 
patients with varying degrees of thrombocytopenia with liver disease (n = 9) (A–C) (platelet counts, 17-55 × 109/L and INR > 1.5) or 
thrombocytopenia secondary to chemotherapy (D–F) (n = 10) (platelet count 9-68 × 109/L); color indicates individual patient samples. TG 
parameters included PH measured in RFU, AUC in RFU, and velocity of thrombin generation, Vmax (RFU/sec). TG was performed without 
PCC and PCC at 3 concentrations corresponding to 0.26, 0.52, and 1.03 IU/mL increase in PCC concentration. Corresponding values for 
normal healthy donors (n = 5, PRP 150 × 109/L) are included for comparison. Data are presented as individual plots with mean ± standard 
error of the mean. P values < 0.05 are considered statistically significant. P values are presented for comparison between no PCC and added 
PCC and between the doses of PCC. AUC, area under the curve; PCC, prothrombin complex concentrate; PH, peak height; PPP, platelet-poor 
plasma; RFU, relative fluorescence unit; TG, thrombin generation; Vmax, maximum velocity
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TG assays with thrombomodulin to evaluate the impact of proteins 
C and S. In addition, it is possible that TF-containing microparticles 
present in the patient plasma samples may have slightly impacted on 
the TG results, but the minimal effect in PPP spiked with PCCs suggest 
that this may not have been that important. Furthermore, it is import-
ant to note the plasma levels achieved after in vivo administration are 
not similar to levels seen following in vitro spiking. Moreover, an in 
vitro laboratory study cannot provide estimates of thrombotic risk, a 
factor that is particularly important to consider in patients with liver 
disease. For example, a clinical trial to evaluate the use of the throm-
bopoietin-receptor agonist eltrombopag to increase platelet count in 
patients with thrombocytopenia and chronic liver disease was termi-
nated due to an increased incidence of portal vein thrombosis in the 
treatment group.31 A study in liver transplant patients with prolonged 
INR confirmed that PCC can effectively restore thrombin generation, 
but noted that the required doses of PCC are lower than for warfarin 
reversal, likely as a result of slow thrombin inhibition.32 A recent study 
confirmed the efficacy of PCC in patients with liver disease, without 
an excess of thrombotic events, and also observed lower dosing with 
PCC compared to anticoagulant reversal.33 Additionally, this study did 
not evaluate interactions with other hemostatic modalities, such as 
desmopressin and antifibrinolytics, and therefore may not fully reflect 
the multifaceted treatments that patients with thrombocytopenia may 
receive in clinical practice.34
In contrast to our ex vivo studies of spiking with PCCs, the in-
creases in the levels of clotting factors in patients, after administration 
of PCCs, are variable due to redistribution of the factors to extravas-
cular compartments, which affect the recovery and half-life. Factor IX 
demonstrates a median recovery of 1.57% and prothrombin 2.11% 
per IU/kg administered to healthy volunteers.35 Through extrapolation 
of the levels from the spiking studies, and by utilizing the median re-
coveries from the healthy volunteer study, the 4 PCC concentrations 
achieved with spiking (0.26, 0.52, 1.03, and 1.53 IU/mL) can poten-
tially be demonstrated in patients receiving PCCs at doses of 17, 33, 
66, or 97 IU/kg, respectively, using factor IX levels and recovery. The 
lower 2 concentrations and doses correlate with doses administered 
to patients in clinical practice, but the higher 2 doses are not recom-
mended for clinical use.
It is critical that the results of the ex vivo spiking study are 
confirmed in samples from patients receiving PCCs for acquired 
coagulopathy. Equally additional TGA analysis with thrombomod-
ulin is important to understand the impact of concurrent increase 
in proteins C and S. Further, similar analysis should be undertaken 
with viscoelastometric tests as they are increasingly used to de-
termine the need for transfusion of blood components. PCCs have 
traditionally been considered as a plasma alternative, but our 
studies show that the influence of PCCs in TG goes beyond simple 
replacement with plasma. The ratio of procoagulants and antico-
agulants is altered with PCCs, and they improved the impaired TG 
of thrombocytopenia and low coagulation factors. Indeed, judi-
cious use of PCCs along with clear algorithms for transfusion of 
blood products have produced a reduction in the quantity of allo-
genic products infused.36
In summary, we have demonstrated for the first time the impact 
of increasing levels of coagulation factors on platelet-dependent TG 
in the context of thrombocytopenia. Our results in PRP TG demon-
strate that increasing the concentration of procoagulant proteins 
in thrombocytopenic samples improves TG to normal ranges and 
higher. These data suggest that further clinical studies would be of 
interest to investigate the role of PCCs in the management of com-
plex coagulopathy characterized by abnormal coagulation and mild 
to moderate thrombocytopenia.
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